RESUMO
BACKGROUND: The opioid epidemic is an international public health concern. Pharmacists are in a strategic position to promote and implement effective opioid stewardship due to both their central role on health care teams and frequent interaction with patients. Despite this integral role, pharmacists do not have harmonized scopes of practice in opioid stewardship. OBJECTIVES: This scoping review was conducted to identify and critically review the role of pharmacists in opioid stewardship and identify future areas of study. METHODS: The scoping review was conducted according to the methodological framework proposed by Arksey and O'Malley, which was further modified by the Joanna Briggs Institute. Six databases were searched for original, peer-reviewed research; PubMed (MEDLINE), Ovid Embase, Ovid International Pharmaceutical Abstracts, Scopus, Cochrane Library, and APA PsycInfo. RESULTS: In 92% of the included studies (n = 77), opioid stewardship interventions led by either a pharmacist or in an interdisciplinary team resulted in improvements in at least one outcome measure, with education and medication therapy adjustments being the most predominant activities. Other areas supported by evidence include community stakeholder education, policy and guideline setting, and risk assessment. CONCLUSION: This scoping review provides valuable insight into the various roles pharmacists can have in opioid stewardship. The findings from this review identified opioid stewardship activities that can make significant contributions towards reducing the impact of the opioid crisis. This review informs future research and has the potential to influence pharmacy practice on a national and international scale.
Assuntos
Assistência Farmacêutica , Farmácias , Analgésicos Opioides/efeitos adversos , Humanos , Farmacêuticos , Papel ProfissionalRESUMO
BACKGROUND: The opioid crisis is a worldwide public health concern. In North America, evidence suggests that the increase in opioid prescriptions correlates with the observed increase in opioid-related mortality and morbidity. Pharmacists are in a strategic position to promote effective opioid stewardship as they have a central role on healthcare teams. However, in many contexts, pharmacists do not have a harmonized scope of practice and no standardized opioid stewardship approach has been implemented. OBJECTIVES: A scoping review will be conducted to identify and summarize evidence on the role of pharmacists in opioid stewardship and identify areas for future study. METHODS: The scoping review will be conducted according to the methodological framework proposed by Arksey and O'Malley, which was further modified by the Joanna Briggs Institute. Six databases will be searched which include PubMed, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and APA PsycInfo. PROJECT IMPACT: The findings of this review will identify opioid stewardship activities that can contribute towards reducing the impact of the opioid crisis. Additionally, it will provide foundational strategies to promote policy level change and foster a harmonized scope of practice. This review has the potential to inform future research, impact pharmacy practice, and drive policy change.
Assuntos
Assistência Farmacêutica , Farmácias , Analgésicos Opioides , Humanos , Farmacêuticos , Prescrições , Literatura de Revisão como AssuntoRESUMO
BACKGROUND: Neuropathic pain (NPP) is a chronic syndrome suffered by patients with multiple sclerosis (MS), for which there is no cure. Underlying cellular mechanisms involved in its pathogenesis are multifaceted, presenting significant challenges in its management. METHODS: A randomized, double-blind, placebo-controlled study involving 15 relapsing-remitting MS patients with MS-induced NPP was conducted to evaluate nabilone combined with gabapentin (GBP). Eligible patients stabilized on GBP (≥1,800 mg/day) with inadequate pain relief were recruited. Nabilone or placebo was titrated over 4 weeks (0.5 mg/week increase) followed by 5-week maintenance of 1 mg oral nabilone (placebo) twice daily. Primary outcomes included two daily patient-reported measures using a 100-mm visual analog scale (VAS), pain intensity (VASpain), and impact of pain on daily activities (VASimpact). Hierarchical regression modeling was conducted on each outcome to determine if within-person pain trajectory differed across study groups, during 63-day follow-up. RESULTS: After adjustment for key patient-level covariates (e.g., age, sex, Expanded Disability Status Scale, duration of MS, baseline pain), a significant group × time(2) interaction term was reported for both the VASpain (P < 0.01) and VASimpact score (P < 0.01), demonstrating the adjusted rate of decrease for both outcomes was statistically greater in nabilone vs placebo study group. No significant difference in attrition rates was noted between treatments. Nabilone was well tolerated, with dizziness/drowsiness most frequently reported. CONCLUSION: Nabilone as an adjunctive to GBP is an effective, well-tolerated combination for MS-induced NPP. The results of this study identify a novel therapeutic combination for use in this population of patients predisposed to tolerability issues that may otherwise prevent effective pain management.
Assuntos
Analgésicos/uso terapêutico , Dronabinol/análogos & derivados , Esclerose Múltipla Recidivante-Remitente/complicações , Neuralgia/tratamento farmacológico , Adulto , Aminas/uso terapêutico , Ácidos Cicloexanocarboxílicos/uso terapêutico , Método Duplo-Cego , Dronabinol/uso terapêutico , Feminino , Gabapentina , Humanos , Masculino , Pessoa de Meia-Idade , Neuralgia/etiologia , Medição da Dor , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
IMPORTANCE OF THE FIELD: In recent times, our knowledge of cannabinoids and the endocannabinoid system has greatly advanced. With expanding knowledge, synthetic cannabinoids - including nabilone, dronabinol and a combination of synthetic Delta9-THC and cannabidiol - have been developed and tested for benefit in a variety of therapeutic indications. AREAS COVERED IN THIS REVIEW: The aim of this article is to provide a summative review of the vast amount of clinical trial data now available on these agents. WHAT THE READER WILL GAIN: To locate clinical trials for review, a literature search was performed using PubMed between the dates of 25 May and 30 June 2009. Search parameters were set to isolate only human randomized controlled trials (RCTs) published between 1990 and 2009. Keywords consistently used for each search include: cannabinoids, marijuana, THC, nabilone and dronabinol. Preferential selection was given to the best-designed trials, focusing on placebo-controlled, double-blind RCTs with the largest patient populations, if available. TAKE HOME MESSAGE: As efficacy and tolerability of these agents remain questionable, it is important that cannabinoids not be considered 'first-line' therapies for conditions for which there are more supported and better-tolerated agents. Instead, these agents could be considered in a situation of treatment failure with standard therapies or as adjunctive agents where appropriate.
Assuntos
Canabinoides/uso terapêutico , Cannabis/efeitos adversos , Terapia Combinada/métodos , Medição da Dor/métodos , Dor/tratamento farmacológico , Atividades Cotidianas , Cannabis/química , Método Duplo-Cego , Dronabinol/análogos & derivados , Dronabinol/farmacologia , Dronabinol/uso terapêutico , Humanos , HipersensibilidadeRESUMO
OBJECTIVE: The purpose of this review is to provide an update of the neuropathic pain treatment algorithm previously published by Namaka et al. in 2004. This algorithm focuses on the strategic incorporation of the latest pain therapies while providing an update of any recent developments involving medications previously listed in the algorithm. DATA SOURCES: PubMed, MEDLINE, Cochrane, and Toxnet databases were used to conduct all literature searches on neuropathic pain and targeted treatment strategies. Comprehensive search efforts in the identified databases included studies published between 1980 and 2009. The search term "neuropathic pain" was used along with each of the agents outlined in this review: pregabalin, paroxetine CR, duloxetine, tramadol XL, Tramacet, Sativex, and nabilone. STUDY SELECTION: A total of 90 studies were reviewed and selected based on level 1, 2, and 3 search strategies. DATA EXTRACTION: Level 1 search strategies were initially aimed at evidence-based trials of large sample size (N > 100), with a randomized, double-blind, placebo-controlled design conducted by investigators well versed in the specialty area of interest. A level 2 search was conducted for additional trials that had many, but not all, of the desirable traits of evidence-based trials. In addition, a level 3 search strategy was conducted to compare key findings stated in anecdotal reports of very small (N < 15), poorly designed trials with the results of well-designed, evidence-based trials identified in level 1 and/or level 2 searches. DATA SYNTHESIS: Based on a thorough evaluation of the literature, pregabalin, paroxetine CR, and duloxetine have been placed in the updated algorithm as first-line agents, while tramadol XL, Tramacet, Sativex, and nabilone function primarily as adjunctive agents. CONCLUSION: The updated algorithm provides a baseline framework from which clinicians can justify the medication they prescribe.
Assuntos
Analgésicos/uso terapêutico , Neuralgia/tratamento farmacológico , Algoritmos , Analgésicos/efeitos adversos , Analgésicos/farmacologia , Cloridrato de Duloxetina , Humanos , Neuralgia/fisiopatologia , Medição da Dor , Paroxetina/efeitos adversos , Paroxetina/farmacologia , Paroxetina/uso terapêutico , Pregabalina , Ensaios Clínicos Controlados Aleatórios como Assunto , Tiofenos/efeitos adversos , Tiofenos/farmacologia , Tiofenos/uso terapêutico , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/farmacologia , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
OBJECTIVE: To review the etiology and treatment strategies for multiple sclerosis (MS). DATA SOURCES: Published information on MS and targeted treatment strategies extending back to 1955. The search terms multiple sclerosis and pathology, prevalence, genetics, and each of the common symptoms of MS were used. STUDY SELECTION: Seventy-two studies were reviewed based on level 1, 2, and 3 search strategies. DATA EXTRACTION: Level 1 search strategy targeted evidence-based trials of large sample size (N > 100) with a randomized, double-blind, placebo-controlled design. A level 2 search targeted additional trials with some of the traits of evidence-based trials. A level 3 search compared key findings in reports of very small (N < 15) poorly designed trials with the results of well-designed trials. DATA SYNTHESIS: MS affects each patient differently, making a definitive diagnosis and management of symptoms very difficult. Effective symptom management requires an interprofessional team approach. CONCLUSION: Despite all the research dedicated to this disease, there is still no cure. The treatments currently available function at best only to slow the disease progression and mitigate symptoms. Using the skills and knowledge available from a team of health care professionals will help patients navigate the trials and tribulations that follow throughout a life with MS.
Assuntos
Esclerose Múltipla/etiologia , Esclerose Múltipla/terapia , Equipe de Assistência ao Paciente , Terapia Combinada , Efeitos Psicossociais da Doença , Humanos , Esclerose Múltipla/diagnóstico , Esclerose Múltipla/fisiopatologia , Prevalência , Qualidade de Vida , Fatores de Risco , Resultado do TratamentoRESUMO
CONTEXT: Despite their increasing need for kidneys and low nonliving donation rates, minimal research has been conducted to ascertain the perceptions of Hispanic Americans about living organ donation and the process of asking for such a donation. OBJECTIVE: To examine perceptions of Hispanics regarding barriers to and benefits of living donation as well as the process of asking someone to be a living donor. DESIGN: A qualitative study consisting of 10 focus groups conducted in 2 series. PARTICIPANTS: Adult Spanish-language-dominant Hispanic members of the general population of Tucson, Arizona. RESULTS: The main barriers to living organ donation were a lack of knowledge or information and fear of the donation process. Knowing that one has helped save or improve another's life was the central benefit. Most participants reported being willing to ask a relative to be a living donor if they were ever in need. Two main responses typified these individuals: no concern about asking because of a strong desire to fight for one's health and for one's family, or asking despite difficulties and concerns about the process. A significant minority of participants indicated they would not ask for a donation, because of either a desire to avoid harming others or the expectation that a relative would initiate an offer.
Assuntos
Atitude Frente a Saúde/etnologia , Conhecimentos, Atitudes e Prática em Saúde , Hispânico ou Latino/etnologia , Transplante de Rim/etnologia , Doadores Vivos/psicologia , Adulto , Altruísmo , Arizona , Família/etnologia , Medo , Feminino , Grupos Focais , Educação em Saúde , Acessibilidade aos Serviços de Saúde/organização & administração , Necessidades e Demandas de Serviços de Saúde/organização & administração , Hispânico ou Latino/educação , Hispânico ou Latino/estatística & dados numéricos , Humanos , Transplante de Rim/estatística & dados numéricos , Doadores Vivos/educação , Doadores Vivos/estatística & dados numéricos , Masculino , Pesquisa Metodológica em Enfermagem , Pesquisa Qualitativa , População UrbanaRESUMO
BACKGROUND: Neutralizing antibodies (NAbs) develop in patients receiving interferon beta (IFN-beta) for multiple sclerosis (MS). Debate continues concerning the relevance of NAb development on treatment efficacy. OBJECTIVE: To determine the incidence and clinical importance of NAbs in patients with relapsing-remitting MS (RRMS). METHODS: A comprehensive literature review was conducted using PubMed (accessed from 1983 to June 2005), Cochrane MS Group trials register (accessed June 2005), MEDLINE (accessed 1983 to June 2005), and Toxnet (accessed June 2005) databases. NAb-induced changes in clinical efficacy and disease progression were evaluated according to the clinical guidelines established by the American Academy of Neurology. RESULTS: Currently, there is no standardized assay to comparatively assess NAbs among different treatments. NAbs develop independent of age, sex, disease duration and progression index at the onset of treatment. The occurrence of NAbs varies from 2-45% depending on the treatment initiated. NAb+ patients demonstrate accelerated disease progression as confirmed by an approximate 1-point increase in the Expanded Disability Status Scale score. The odds of relapse during a NAb+ period are between 1.51 and 1.58 (p < 0.03) with the time to first relapse being shortened by an average of 244 days after 12 months of IFN-beta therapy. NAb+ patients experience an approximately four-fold increase (p = 0.009) in the median number of active T2 magnetic resonance imaging (MRI) lesions compared to NAb-negative patients (1.4 vs. 0.3 respectively, p < 0.01). CONCLUSION: The induction of NAbs in IFN-beta treated patients reduce clinical effect and accelerate disease progression.